Entecavir Therapy for Adefovir-Resistant Hepatitis B Virus Infection in Kidney and Liver Allograft Recipients

The aim of our study was to assess the efficacy and safety of entecavir in kidney- and liver-transplant recipients with chronic hepatitis B virus (HBV) infection. Ten male transplant patients with chronic HBV infection (eight kidney- and two liver-transplant patients), who have become adefovir (n=9) or lamivudine-resistant (n=1) were given entecavir at 0.5 to 1 mg/d. All patients were HBs Ag positive: six were HBe Ag(−)/HBe Ab(+), and four were HBe Ag(+)/HBe Ab(−). After a median follow-up of 16.5 months, entecavir therapy was associated with a significant decrease in HBV DNA viral load, that is, 3.86 (2.71–6.46) log10 copies/mL at baseline down to 2.94 (2.15–4) log10 copies/mL at last follow-up (P=0.004). Rate of HBV DNA clearance was 50% in both HBeAg(+) and HBeAg(−) patients. There were no significant changes in renal function or hematological parameters. This study demonstrates that entecavir therapy is safe and efficient in HBV(+) organ-transplant patients.

[1]  D. Moradpour,et al.  Hepatitis C virus infection in haemodialysis and kidney transplant patients , 2008, Reviews in medical virology.

[2]  M. Kim,et al.  Clinical outcome of renal transplantation in patients with positive pre‐transplant hepatitis B surface antigen , 2007, Journal of medical virology.

[3]  J. Encke,et al.  Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  R. Gish.  Improving outcomes for patients with chronic hepatitis B , 2007, Current gastroenterology reports.

[5]  J. Dumortier,et al.  Rejection Under Alpha Interferon Therapy in Liver Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  H. J. de Silva,et al.  Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. , 2006, Transplantation proceedings.

[7]  R. Gish,et al.  Hepatitis B in liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  E. Schiff,et al.  Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues , 2006, Annals of Clinical Microbiology and Antimicrobials.

[9]  S. J. Matthews,et al.  Entecavir for the treatment of chronic hepatitis B virus infection. , 2006, Clinical therapeutics.

[10]  S. Pol,et al.  Efficacy and Safety of Adefovir Dipivoxil in Kidney Recipients, Hemodialysis Patients, and Patients with Renal Insufficiency , 2005, Transplantation.

[11]  L. Rostaing,et al.  Effects of long-term lamivudine therapy in renal-transplant patients. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  C. Ponticelli,et al.  [Natural history of HBV in dialysis population]. , 2004, Giornale Italiano di Nefrologia.

[13]  Adefovir dipivoxil: new preparation. A third-line option in chronic hepatitis B. , 2004, Prescrire international.

[14]  G. Gerken,et al.  Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for chronic hepatitis B infection , 2002 .

[15]  Y. Chrétien,et al.  HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. , 2000, Transplantation.

[16]  P Coriat,et al.  Impact of hepatitis B and C virus on kidney transplantation outcome , 1999, Hepatology.

[17]  M. Bennett,et al.  Nucleoside analogue therapy in fibrosing cholestatic hepatitis--a case report in an HBsAg positive renal transplant recipient. , 2008, Liver.

[18]  Z. Gaciong,et al.  Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. , 1998, Transplant international : official journal of the European Society for Organ Transplantation.

[19]  L. Rostaing,et al.  Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. , 1997, Transplantation.

[20]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[21]  F. Carnot,et al.  The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. , 1996, Transplantation.

[22]  L. Rostaing,et al.  Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. , 1996, Nephron.

[23]  H. Okamoto,et al.  A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. , 1995, Kidney international.

[24]  J. T. Liang,et al.  Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigens: a case report of fibrosing cholestatic hepatitis. , 1995, Hepato-gastroenterology.

[25]  D. V. van Thiel,et al.  Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease , 1991, Hepatology.

[26]  F. Carnot,et al.  Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. , 1988, Gastroenterology.